Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGUANGZHOU, China, September 27,2021 (BUSINESSWIRE) –Bio-Thera Solutions, Ltd. (688177.SH, “Bio-Thera”)and Intract Pharma (“Intract”) announced a global collaboration and licensingagreement that gives Bio-Thera access to Intract’s Soteria® and Phloral® drugdelivery technologies to devel...
GUANGZHOU, China, September 8, 2021 (BUSINESSWIRE) --Bio-Thera Solutions, Ltd. (688177.SH) today announced that it has entered into a commercialization and license agreement with Sandoz to commercialize BAT1706, an anti- vascular endothelial growth factor (VEGF) monoclonal antibody that is a propose...
Guangzhou and London, 27 August 2021 – Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar referencing Stel...
